All studies
CompletedPhase IVInterventional

Feasibility trial: temporary reduction in the number of antiviral medicines people with both HIV and HBV infection need to take

Many people living with both HIV and hepatitis B take a combination of antiviral medicines that includes tenofovir. Tenofovir is very good at keeping both viruses quiet, but taking it for many years can sometimes cause unwanted effects on the bones and kidneys. Today, many people who only have HIV can safely manage with fewer drugs. Researchers want to find out if the same is possible for people living with both conditions. This trial at King's College Hospital will involve 12 adults whose HIV and hepatitis B are already well controlled. Participants will stop taking tenofovir for six months while continuing their other antiviral medicines. Doctors will monitor them very closely with regular blood tests to make sure both viruses stay dormant. Tenofovir will then be restarted. The results will help doctors decide if a larger trial is safe to run.

At a glance

Status
Completed
Phase
Phase IV
Sponsor
King's College Hospital NHS Foundation Trust
Enrolment target
12
Start
21 Aug 2022
Estimated completion
01 Mar 2025

What is this study about?

Living with both HIV and hepatitis B usually means taking a combination of daily antiviral tablets. One standard medicine is tenofovir, which works against both viruses at the same time. While it is very effective, taking it over many years can sometimes weaken your bones or affect how well your kidneys work. Finding ways to reduce the number of medicines people take could help prevent these long-term issues.

Doctors have recently discovered new, highly sensitive blood markers. These tests can show whether hepatitis B is completely dormant or if tiny amounts are still trying to multiply. In people whose virus is deeply dormant, it may be possible to pause tenofovir without the virus waking up. This approach has already shown promise in people who have hepatitis B on its own.

This study, called REFINE-B, is a small pilot trial running in London. It aims to test whether pausing tenofovir for six months is safe and practical for 12 people living with both HIV and hepatitis B. If successful, this research could lead to larger studies and eventually give patients simpler, gentler treatment options in the future.

Key takeaways

  • A small UK study testing whether people with both HIV and hepatitis B can safely pause one medicine (tenofovir) for six months.
  • Aims to find out if reducing daily medicines can help prevent long-term bone and kidney side effects.
  • Participants continue taking their other daily HIV tablets throughout the study.
  • Safety is closely protected with 10 clinic check-ups and five phone calls over seven months.
  • Travel expenses are covered, and you will receive £200 for your time.

Who may be eligible?

This study is open to adults aged 18 and over who are living with both HIV-1 and hepatitis B. To take part, both viruses must have been kept completely under control (undetectable in blood tests) on your current medication for at least three years. Your liver must also be in good health, without significant scarring or stiffness.

Before joining, doctors will run special blood tests to ensure your hepatitis B is sleeping deeply enough for it to be safe to pause medication. You must also be willing to use condoms or avoid sex during the seven-month study period, which ensures there is no chance of passing either virus to a partner if viral levels change.

You cannot take part if you have other liver infections (such as hepatitis C or hepatitis D), a history of drug resistance to your current treatments, or other significant liver diseases. The study is also not suitable for anyone who is currently pregnant or breastfeeding.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with both HIV-1 and hepatitis B.
  3. Both infections have been undetectable on stable medication for at least three years.
  4. I do not have severe liver scarring (cirrhosis) or other hepatitis infections.
  5. I am not pregnant or breastfeeding.
  6. I am happy to use condoms or abstain from sex during the study.
Answer every question to see your result.

What does participation involve?

Taking part lasts for about seven months in total. During the study, you will stop taking your tenofovir (or entecavir) tablet for six months, but you will continue taking your other daily HIV medicines exactly as prescribed. To ensure you stay safe, you will visit King's College Hospital 10 times for health checks and blood tests—which is more frequent than standard NHS care. The study team will also ring you five times between visits to check how you are feeling. After six months, you will restart tenofovir. You will receive £200 to thank you for your time, and your travel expenses will be reimbursed.

Potential risks and benefits

Taking part will not directly improve your own health, as you will restart your original medicine after six months. However, your participation will help doctors learn whether simplifying treatment is safe for others in the future. The main risk is that hepatitis B could become active again when tenofovir is stopped, which can irritate the liver. To keep you safe, the team will only enrol people with deeply quiet virus, will monitor your blood frequently, and will restart treatment immediately if there are any signs of a flare-up. You will have 24-hour emergency phone numbers, and you are free to leave the study at any time without it affecting your standard NHS care.

Locations (1)

  • -
    Approximate
    -, England

Common questions

Will I have to stop taking all my HIV medicines?

No. You will only pause one specific drug (tenofovir or entecavir). You will carry on taking your other daily antiviral tablets as normal.

Why do I need to use condoms during the trial?

While it is unlikely, pausing a medicine could allow virus levels to rise briefly. Using condoms guarantees that neither HIV nor hepatitis B can be passed on to a partner.

What happens if my hepatitis B levels start to rise?

Your regular blood tests will catch any changes very early. If the virus begins to wake up, your doctors will restart tenofovir straight away to protect your liver.

How many clinic visits are involved?

You will have 10 hospital visits over seven months, along with five brief catch-up phone calls from the study team.

Will I be paid for taking part?

Your travel costs will be refunded, and you will receive £200 to compensate you for the extra time and hospital visits.

How to find out more

Mariusz Racz

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.